To develop models of human cancer we have expressed the avian retroviral receptor, TVA, under a variety of mammalian promoters in transgenic mice, thus rendering mice susceptible to infection with avian leukosis virusderived gene vectors. TVA-based retroviral gene transfer oers advantages over current murine models of human cancer. A single transgenic mouse line can be used to evaluate multiple genetic lesions, individually and in combination. Furthermore, mutant genes are introduced somatically into animals, as occurs in the majority of naturally occurring tumors. Because the avian viral vectors replicate only in avian cells, the viral receptor in infected transgenic mouse cells remains available for multiple rounds of infection with dierent ASLV vectors. We discuss the theoretical and practical aspects of using recombinant avian retroviruses with TVA transgenic mice to generate cancer models.
Introduction
Current research on tumorigenesis seeks to understand the molecular events driving tumor formation. One goal of this research is to identify targets for the development of novel therapeutics. Gene knockout and transgenic mice have yielded signi®cant insights into the contribution of speci®c mutations to tumorigenesis. However they have several limitations: mutations are germline, with potential to aect tissue development and predispose to neoplasia all cells of a tissue or a mouse. In contrast, in the majority of human cancers, most mutations occur somatically in a single cell (Kinzler and Vogelstein, 1996) . In addition, in most transgenic models, only one or two genetic lesions are controlled by the investigator, but several mutations are likely required to produce most human tumors (Adams and Cory, 1991; Hanahan, 1988; Macleod and Jacks, 1999) . Furthermore, studying interactions of germ line mutations requires extensive, expensive, and time-consuming breeding protocols.
We have sought to develop another strategy to circumvent some of the limitations of typical transgenic and gene knockout tumor models. This strategy is based on use of the receptor for subgroup-A avian leukosis virus, TVA, and allows multiple genes to be introduced somatically into a single transgenic mouse strain (Federspiel et al., 1994; Holland et al., 1998a) . TVA-based tumor modeling systems rely on tissue-speci®c or generalized expression of a transgene encoding TVA; the appearance of TVA on the surface of mammalian cells is sucient to mediate retroviral infection by subgroup A avian sarcoma leukosis viruses (ASLVs) Young et al., 1993) . For the purposes of our studies, we have constructed ASLV vectors by adapting the RCAS vectors popularized by Hughes and colleagues (Hughes et al., 1987) to carry dominant negative tumor suppressors (e.g. mutant p53), oncogenes (e.g. c-myc, k-ras), marker genes (e.g. alkaline phosphatase, green¯uorescent protein), and recombinases (e.g. Cre). (For a complete listing of our available RCAS vectors, see http://rex.nih.gov/RESEARCH/basic/var mus/tva-web/tva2.html)
Background and methods

TVA structure and function
The tv-a gene was cloned from chicken and quail DNA based on its ability to allow infection of mammalian cells by ASLV-A carrying selectable markers Young et al., 1993) . mRNA transcribed from the avian tv-a gene is alternatively spliced to produce at least two proteins ± a transmembrane and a GPI-anchored isoform. These two isoforms have identical 83 amino acid (aa) extracellular domains, and both are sucient to permit infection of mammalian cells. While there is no recognized mammalian homolog, a 40 aa region in the extracellular domain is related to a cysteine-rich element repeated seven times in the low density lipoprotein receptor, LDLR . TVA's role in avian biology, other than acting as a receptor for subgroup avian leukosis viruses, is unknown.
Production of high titer ASLV stock in an avian cell line
To produce high titer recombinant viral stock, we have taken advantage of a Rous Sarcoma Virus (RSV)-derived replication-competent cloning vector, RCAS (Boerkoel et al., 1993; Greenhouse et al., 1988; Hughes et al., 1987; Petropoulos and Hughes, 1991) , and an established chicken ®broblast cell line, DF1 (SchaeferKlein et al., 1998) . RCAS was derived from RSV-A by replacement of the src gene with a multicloning site that stably accommodates inserts up to at least 2.5 kb *Correspondence: HE Varmus (Boerkoel et al., 1993; Greenhouse et al., 1988; Hughes et al., 1987; Petropoulos and Hughes, 1991) . Transfection of RCAS plasmid DNA into DF1 cells results in production of high titer, replication-competent viral stock ( Figure 1a ). Successful transfection of only a few DF1 cells is sucient since the replication-competent virus spreads throughout the DF1 culture (SchaeferKlein et al., 1998) .
ASLV-A infection of mammalian cells
Infection of mammalian cells with subgroup-A avian sarcoma leukosis viruses (ASLV-A) occurs at a low eciency (51610 6 ) in the absence of TVA. However, mammalian cells engineered to express TVA are highly susceptible to infection by ASLV-A (Figure 1b) . After entry into mammalian cells, a newly synthesized DNA copy of the viral genome integrates into the host DNA, and viral LTRs promote high level transcription of integrated provirus. An arti®cial splice acceptor in RCAS, downstream of env, is used for ecient processing of the mRNA representing the insert at the multicloning site (Hughes et al., 1987) . However, no infectious viral particles are made (S Hughes, NIH-NCI, personal communication; Figure 1b ). This has several advantages for our purposes. First, there is no spread of virus to adjacent or distant cells. Second, the TVA receptor is not blocked by infectious particles containing Env protein, and is thus available for multiple rounds of infection (Holland et al., 1998a) .
A ®rst test: a-actin promoter-tv-a transgenic mice
The ®rst demonstration that expression of a tv-a transgene in speci®c mouse tissues could be used in combination with recombinant ASLV-A to introduce foreign genes was performed with a tv-a transgene under the control of the chicken a-sk-actin promoter (Federspiel et al., 1994) . The mice expressed TVA in skeletal and cardiac muscle. A week following direct injection of RCAS-alkaline phosphatase (RCAS-AP) virus supernatant into the leg muscle of newborn mice, variably intense AP-positive muscle ®bers were observed at the site of injection; the variations in staining presumably re¯ect dierences in transcriptional activity at dierent sites of proviral integration and perhaps dierent multiplicities of infection. An important observation from these initial experiments was that infection eciency decreased dramatically after the neonatal period, likely re¯ecting the known requirement of cell division for ecient infection with retroviruses other than lentiviruses (Naldini et al., 1996; Roe et al., 1993) . In newborn mice, myoblasts are numerous, actively dividing, and thus readily infectable with recombinant ASLV-A (Federspiel et al., 1994) . This ®rst in vivo experiment showed that the tv-a-based retroviral system was a viable means of introducing foreign genes into newborn mice in a tissue-speci®c manner.
First use of tv-a transgenic mice to model human cancer: gliomagenesis
We ®rst used tv-a-based technology to induce cancer in mice in our studies of gliomagenesis. Two lines of tv-a transgenic mice were generated (Holland et al., 1998a; Holland and Varmus, 1998) . The ®rst expressed tv-a under the control of the astrocyte-speci®c glial ®brillary acidic protein (GFAP) promoter. In the second line, tv-a expression was controlled by the nestin promoter, which should direct expression of tv-a in glial precursors earlier in the astrocyte lineage. Both lines permit ecient glia-speci®c transfer of genes carried by ASLV-A vectors (RCAS), in vitro and in vivo.
As an initial test of the utility of our strategy, we infected newborn GFAP-tv-a mice with a combination of RCAS-basic ®broblast growth factor (RCAS-bFGF) and RCAS-AP. The number and the distribution of AP-positive cells several weeks later revealed that bFGF promotes extensive glial cell proliferation and migration in vivo, but without induction of frank tumors (Holland and Varmus, 1998) . This implied that bFGF might contribute to the tendency of high grade gliomas to in®ltrate into normal brain parenchyma, but that other genetic lesions are required to produce gliomas.
By crossing tv-a transgenic mice with mice carrying targeted mutations in tumor suppressor genes, we studied combinations of gain-of-function with loss-offunction mutations. In particular, we used this to approach to produce glioma-like lesions in mice by recapitulating the combinations of mutations found in human gliomas (Ichimura et al., 1996; Schmidt et al., 1994) . Human gliomas have shown mutations in genes encoding proteins in signal transduction pathways mediated by tyrosine kinase receptors and in governing the G1 to S transition in the cell cycle. To recapitulate these alterations, we generated RCAS vectors encoding Cdk4 and a naturally-occurring, constitutively-active mutant form of the epidermal growth factor receptor (EGFR) denoted EGFR*. We also crossed our tv-a transgenics to mouse lines with targeted inactivating mutations in p53 or Ink4a/Arf (Holland et al., 1998a) .
We found that gene transfer of EGFR* alone to either GFAP-tv-a or nestin-tv-a mice did not result in formation of tumors. However, transfer of EGFR* to astrocytes from Ink4a/Arf de®cient mice produced glioma-like lesions. The lesions were more frequent in the nestin-tv-a mice, possibly indicating that gliomagenesis is more ecient in less dierentiated cells. Furthermore, EGFR* did not induce lesions in p53-de®cient mice unless Cdk4 was transferred along with EGFR*. These ®ndings demonstrated a collaboration between disruption of the G1 arrest pathways and expression of a mutant form of EGFR in gliomagenesis.
Infection of cultured primary cells from GFAP-tv-a transgenic animals
The TVA-based system allows ecient gene transfer to cultured primary cells (Holland et al., 1998b) . This allowed us to study, in primary astrocyte cultures, the G1 cell cycle arrest pathways that are disrupted in most immortalized cell lines and tumors. By comparing the eects of infection with RCAS(Cdk4) with an absence of Ink4a/Arf we found that both an absence of Ink4a/Arf and overexpression of Cdk4 allowed cells to escape senescence and proliferate inde®nitely in culture.
Cells overexpressing Cdk4 grow more slowly, and importantly shift to a hyperploid status at a high frequency (Holland et al., 1998b) . However, when Cdk4 was overexpressed in Ink4a/Arf de®cient astro- Figure 1 (a) Chicken DF-1 cells are transfected with a plasmid encoding the replication-competent, sub-group A avian viral vector RCAS which contains the viral genes gag, pol and env and a gene of interest (gene X). The virus is produced in high titer and can infect avian cells through the attachment of its surface glycoproteins to the extracellular domain of the TVA receptor on the cell surface. (b) Mammalian cells do not encode the TVA receptor and therefore are not susceptible to virus infection. However, mammalian cells engineered to express tv-a cDNA under a tissue-speci®c promoter are susceptible to the viral infection. Unlike avian cells, mammalian cells do not produce infectious RCAS. Only the protein encoded by gene X is eciently produced in mammalian cells. The lack of viral envelope protein production leaves the TVA receptor unoccupied, permitting repeated infection of mammalian cells with dierent RCAS viruses from chicken producer cells cytes, the cells did not become hyperploid. This implies that one or both products of Ink4a/Arf are required for Cdk4 to promote hyperploidy in primary cultured astrocytes (Holland et al., 1998b) .
Other tumor models in development
We are developing additional TVA-based models of some common human cancers, including breast, lung, ovarian, pancreatic, and melanocytic cancer. Each model presents unique technical challenges and has spurred the development of several novel approaches that further expand the¯exibility of the system.
Breast cancer
To study breast cancer, we have created two lines of TVA transgenic mice, mouse mammary tumor virus LTR-tv-a (MMTV-tv-a) and whey acidic protein promoter-tv-a (WAP-tv-a) (Y Li, unpublished results). The MMTV LTR directs expression in ductal epithelial cells of the mammary and salivary glands, and MMTV-tv-a mice are predicted to express TVA in breast epithelium from early breast development onward. WAP-tv-a mice are expected to express TVA in the breast epithelium only during late pregnancy and lactation (Nagasawa et al., 1996) . Infection by direct injection of virus-producing DF1 cells into the glands of pregnant females oers two advantages over infection of glands in virgin animals: the glands are larger and thus easier to inject, and many cells are undergoing cell division, a requirement for ASLV infection.
We are currently adapting conditional knockout technology to the TVA-based system in the mammary gland. For example, we have crossed our MMTV-tv-a mice to mice whose BRCA1 gene contains Lox-P sites anking exon 11 (BRCA1¯/¯) (Xu et al., 1999) . MMTV-tva/BRCA1¯/¯mice can be infected with RCAS-Cre, which should mediate excision of sequences between Lox-P recognition sites (exon 11 of BRCA1 in this example). As compared to using adenoviral-Cre vectors, there are two potential advantages of using RCAS-Cre to infect MMTV-tv-a/BRCA1¯/¯mice; Cre will be delivered only to the mammary epithelium by RCAS-Cre, and RCAS does not appear to be a potent immunogen.
Lung cancer
To evaluate the functional contribution of speci®c mutations to bronchogenic tumorigenesis, we generated transgenic C57BL6/J mice in which TVA is produced under the control of the 3.7 kb human surfactant protein-C (hSPC) promoter (Korfhagen et al., 1990) . We chose C57BL6/J (as opposed to the FVB strain more commonly used to generate transgenic mice) to minimize the contribution of unidenti®ed loci to bronchogenic tumorigenesis; C57BL6/J mice have a signi®cantly lower predisposition than FVB to develop spontaneous bronchogenic carcinoma (Oomen et al., 1991) . The hSPC promoter directs TVA expression in the type II airway epithelial cells (Glasser et al., 1994; Wert et al., 1993) , and AEC-11 cells are candidate precursors of bronchogenic adenocarcinoma (Belinsky et al., 1992; Re et al., 1992; Rehm et al., 1988; Ward et al., 1985) . Infectability of SPC-tv-a mice was ®rst demonstrated ex vivo by culturing day 14 embryonic lungs with a mitogen keratinocyte growth factor (hKGF) and a marker virus (RCAS-GFP), which resulted in infection of approximately 30% of the distal lung bud cells (GH Fisher, unpublished results). We have begun in vivo infection of neonatal AEC-II by injection of concentrated RCAS viral vectors (titer 1610 9 /ml) into amniotic¯uid on gestational day 14. As opposed to infection of adult lung, in utero infection has two main advantages: SPC-expressing cells are actively dividing (Voelker and Mason, 1989) , and embryonic exposure to antigen is potentially tolerogenic (Sarzotti, 1997) . Disadvantages include a requirement for timed pregnant females, time-consuming operations, and, most importantly, low pup survival (less than 50%, unless pups are fostered). Because of the cumbersome nature of in utero infection we are currently pursuing ecient ways to infect newborn and adult animals.
Pancreatic cancer
We have generated two lines of transgenic mice that should express TVA in pancreatic acinar cells, under control of the pancreatic elastase promoter and pancreatic amylase promoter (BC Lewis, unpublished results). Mitotic rates of adult pancreatic acinar cells are exceptionally low (Elsasser et al., 1986) . Since ASLV infection requires cell division, we are devising an alternate infection strategy that does not require target cell division. Unlike most retroviruses, lentiviruses (such as HIV) do not require mitosis for proviral integration (Naldini et al., 1996) . We are currently adapting a lentiviral HIV vector to our TVAbased pancreatic carcinoma model. To do this, we cotransfect a plasmid encoding the envelope protein for avian leukosis virus subtype-A, Env-A, together with a plasmid encoding HIVgag, pol, and a third plasmid containing only the HIV-LTRs¯anking the gene of interest and a packaging signal (Naldini et al., 1996) . The resultant pseudotyped virus vector is able to infect cell lines expressing TVA with a titer of approximately 5610 4 ± an eciently approximating that of RCAS vectors generated in the same cell line after transient transfection (BC Lewis and N Chinnasammy, unpublished results). We are currently testing the ability of pseudotyped lentiviruses to infect non-replicating murine cells.
Ovarian cancer
In our studies of ovarian cancer, we have taken a slightly dierent approach because there are currently no characterized promoters that speci®cally direct expression to the ovarian epithelium, the presumptive precursor to ovarian carcinoma. We have used physical, instead of molecular, means to introduce speci®city to our TVA-based ovarian cancer studies. To infect the ovarian epithelium, we excise the ovaries from a line of transgenic mice ubiquitously expressing TVA under control of the b-actin promoter (Federspiel et al., 1996) , and infect the ovarian epithelial cells in culture (S Orsulic, unpublished results). In this manner, any organ of interest from b-actin-TVA mice (ovary in this case) can be speci®cally infected in culture. After one or more rounds of infection, the cells can be studied in vitro by monitoring changes in cell growth, morphological alterations, chromosomal abnormalities, and changes in gene expression, or they can be reimplanted into syngeneic or nude (nu/nu) hosts ( Figure  2 ). One caveat to using physical instead of molecular means to introduce speci®city is that isolation of the cell type of interest is the limiting factor determining speci®city. For example, within an ovary there are multiple cell types besides epithelial cells, including thecal, germ, granulosa, endothelial, and ®broblastic cells.
Melanoma
We generated mice expressing TVA under the control of the tyrosinase-related protein-2 (TRP2) promoter (Steel et al., 1992) . This promoter directs expression to early melanoblast lineages as well as in early neural crest cells (W Pavan, personal communication, NHGRI). To date we have been able to demonstrate expression of TVA in neonatal melanocytes and neural crest cells derived from these mice. Furthermore, neural crest cells derived from these mice can be infected with RCAS viruses (BO Williams, unpublished results, in collaboration with the laboratory of W Pavan, NHGRI). We are currently optimizing methods for in vivo infection of melanoblasts.
TVA-based studies of neural, hemapoietic, and other organ development TVA-based systems are also proving to be useful in development studies. Doetsch and colleagues recently used our GFAP-tv-a transgenic mice to demonstrate that GFAP-positive astrocytes of the subventricular zone (SVZ) act as neural stem cells. They tracked the fate of AP-positive progeny cells following RCAS-AP infection of SVZ astrocytes in vivo. Three and one half days after infection, AP-positive migrating neuroblasts appeared and, by 14 days after infection, AP-positive mature neurons were found in the olfactory bulb (Doetsch et al., 1999) .
Leavitt and colleagues generated mice expressing TVA under control of the megakaryocyte-lineage restricted promoter, GP-Iba (Murphy and Leavitt, 1999) . Cells of the megakaryocyte lineage from these mice were readily infectable both in vitro and in vivo. Simple intra-peritoneal injection of viral supernatant was sucient to infect a large proportion of megakaryocyte precursors. This TVA-based model was used to demonstrate that IL-3 stimulates cell division, while inhibiting maturation of early megakaryocyte-lineage cells.
Another developmental application of TVA-based gene delivery is in the study of lung development (J Yingling, Vanderbilt University, personal communication). In this model, lung buds from SPC-tv-a Figure 2 Retroviral gene delivery to mammalian cells engineered to express avian TVA receptor. DF-1 chicken cells transfected with an RCAS vector carrying a gene of interest are propagated to obtain high titer virus particles. Producer DF-1 cells, cell supernatant, or concentrated viruses are used to infect a tv-a-expressing transgenic mouse. The TVA-receptor is produced only in cells in which the transgenic promoter is active, and only these cells are then susceptible to virus infection. Tissue-speci®c infection can be achieved by direct injection of virus or virus-producing cells into an organ in which TVA is produced or by systemic injection of virus into mice expressing the TVA transgene in selected cell types. Alternatively, an organ of interest can be removed and its cells propagated in vitro to facilitate multiple rounds of infection. A combination of several RCAS viruses carrying dierent genes of interest (i.e. oncogenes, dominant-negative tumor suppressor genes and markers) can be used for infection simultaneously or sequentially. After short-term culture, the infected primary cells can be re-implanted into recipient mice. In addition, the infected primary cells can be studied in culture transgenic mice are cultured on embryonic day 11 and infected with dierent RCAS viruses to assess eects on branching morphology in in vitro culture systems.
Practical considerations
Construction of TVA-transgenic mice
Choice of promoter Generalized, tissue-speci®c, and lineage-speci®c promoters have all been successfully used to construct TVA-transgenic mice (Federspiel et al., 1996; Holland et al., 1998a; Murphy and Leavitt, 1999) . Each approach oers distinct advantages as outlined previously.
TVA isoform As mentioned earlier, at least two TVA isoforms have been identi®ed; a GPI-linked isoform encoded by an 800 bp cDNA and a transmembrane isoform encoded by a 950 bp cDNA. The GPI-linked isoform has been used in the majority of tv-atransgenic mice reported to date (Federspiel et al., 1996; Holland et al., 1998a) . The transmembrane isoform was recently used by Leavitt and colleagues in their studies of the megakaryocyte lineage (Murphy and Leavitt, 1999) . De®nitive comparison of these two isoforms has not been performed, but it is apparent that both have conferred infectivity on mammalian cells in vitro and in vivo. In the most extensive side-byside comparison, using both transiently and stably transfected human T-cells (Jurkat cells), the transmembrane form appeared to promote infection slightly more eciently (1.2-fold) than the GPI-linked form (GH Fisher, unpublished results).
Delivery of virus vectors
As indicated in the preceding sections, there are now several means to deliver RCAS vectors to TVA transgenic mice, and the strategy chosen will be in¯uenced by several factors, including accessibility and replication of target cells, the pattern of expression of TVA, the goals of the experiment, and the need for multiple infection of individual cells. Here we brie¯y consider some of the factors and how they might guide the strategy for delivery of vectors.
Mitotic activity of target cells Target cells must be actively replicating for successful infection with RCAS viruses. In some organs, such as the skin, dierentiated cells are regenerated throughout adult life from stem cells, and higher proliferation can be induced by skin abrasion. In other organs, such as the breast and the ovary, epithelial cells proliferate in response to hormonal stimulation. To optimize infection, virus delivery should be coordinated with maximum cell proliferation or enhanced by treatment with hormones. In most organs, such as the muscle and the lung, mitotic activity during embryonic development subsides dramatically soon after birth. In these cases, the optimal time for virus delivery is in the neonatal period.
Injecting viruses or virus-producing cells
The simplest way to deliver RCAS virus is to inject DF-1 producer cell supernatant into a mouse. It may help to concentrate virus by centrifugation or other means to infect small targets (e.g. developing organs in mouse embryos or newborn mice). Viruses can also be delivered by injecting virus-producing DF-1 chicken cells, which will continue to produce RCAS vectors for several days, thus prolonging the time of infection and increasing the exposure of target cells to the vectors. A disadvantage to this method is the possibility of an in¯ammatory response against the chicken producer cells.
Systemic vs localized virus delivery Successful infection of dierent organs with RCAS viruses depends greatly on the route of viral delivery. Intraperitoneal or intravenous infection of adult mice has been used to deliver viruses to the megakaryocytic lineage (Murphy and Leavitt, 1999) and to endothelial cells (Y Li, unpublished results). However, the titer is likely to be low when virus reaches the target cells or organs, so double infection with this approach will consequently be low. Direct injection of the virus or virus-producing cells into a selected area of an organ (e.g. the brain or a duct of the mammary gland) should increase the possibility of double infection (Holland and Varmus, 1998) . Additionally, the trauma caused by the needle at the site of injection may induce proliferation of certain types of target cells and therefore increase the chance of infection (Holland and Varmus, 1998) .
Delivering virus in vitro or in vivo In most cases, we have infected TVA transgenic mice by injecting RCAS viruses systemically or by injecting viruses or virus-producing cells directly into an organ of interest. Alternatively, the organ of interest can be isolated and its cells grown in vitro where they can be subjected to repeated infections with the same or dierent viruses (Figure 2) . Injection in the animal more accurately resembles tumor formation in its natural microenvironment, since the organ structure is preserved. But the eciency of infection (and multiple infection) is dependent on the accessibility of the organ and the proliferation rate of target cells. More ecient viral delivery can be achieved in vitro due to induced cell proliferation and the possibility of repetitive exposure of all cells to high titer stocks. This is the preferred method for infections with multiple viruses, which can be introduced simultaneously or sequentially. In addition, changes in cell growth, apoptosis, adhesion, protein expression and chromosome number and structure can be easily monitored at multiple time points, even without returning the cells to the animal. Cells infected in vitro with various combination of viruses can also be re-introduced into genetically identical hosts ± and, in some cases (e.g. ovary), even into the host from which the cells were obtained ± to ask whether tumors occur and how they behave.
Immune response
Infection of mammalian cells with RCAS vectors introduces genes encoding foreign viral and cellular proteins that could potentially elicit an immune response. In our most developed tumor model, gliomagenesis, immune-mediated rejection of RCASinfected tissue was not observed. Furthermore, we have seen stable expression of alkaline phosphatase several weeks following infection of adult MMTV-tv-a mice. It is unknown whether an immune response occurs against viral proteins or proteins encoded by the introduced gene.
Multiple and sequential in vivo infections
While it is theoretically possible to perform multiple sequential infections in vivo, we have found that we usually infect only a subset of cells within the target tissue (e.g. a subset of the cells that surround the needle tract in the CNS). If we assume a 15% random infection rate in a target tissue and infect sequentially with three viruses (a,b,c), eight cell types would be generated ± non-RCAS infected, a, b, c, ab, ac, bc, abc. However, only 0.34% of the cells would contain all three viruses. Sequential in vivo infections (as opposed to facile sequential infections performed in vitro) are extremely unlikely to produce pure populations of multiply infected cells. However, a heterogeneous pool of multiply infected cells within one target tissue is advantageous for studies of tumorigenesis because any tumors that arise can be excised and genotyped. Thus, one mouse can yield multiple tumors with multiple genotypes and phenotypes.
Limited insert size and RCAS stability
One potential limitation of this system is the approximately 2.5 kb insert size limit of RCAS. This has not been a signi®cant problem for our current projects because cDNAs derived from most oncogenes we study are less than 2.5 kb, or well characterized, naturally-occurring oncogenic variants of less than 2.5 kb have been available. This may not be the case for all genes that an investigator wishes to study. One solution to this limitation is to pseudotype (with ASLV-A Env) viral vectors derived from replicationdefective Moloney murine leukemia virus, MLV. Pseudotyped MLV vectors have carrying capacity up to 6 ± 7 kb (Soneoka et al., 1995) and can be eciently pseudotyped with ASLV envelope protein (Murphy and Leavitt, 1999) . Although pseudotyping allows generation of virus with large inserts viral titers may be lower than those achieved in DF1 cells with replication competent RCAS vectors.
Summary
We have made signi®cant advances in the development of a novel retrovirus-based system to investigate the roles of speci®c mutations in tumorigenesis. The TVAbased gene delivery system oers several advantages over transgenic and gene knockout tumor models. First, the vector is replication-competent in avian cells, allowing for the generation of high titer viral stock. (Titers of 1610 9 /ml are possible after concentrating the DF1 cell supernatant). Second, infected mammalian cells do not produce infectious virus, allowing multiple infections. Third, a single transgenic line of mice can be used for the study of multiple mutations; this simpli®es breeding, saving both time and money. Fourth, TVA transgenic mice can be bred with tumor-suppressorde®cient mice to study potentially cooperative mutations. Fifth, speci®city of infection is determined by the pattern of expression of the TVA transgene, allowing for developmental and tissue-speci®c infection. Furthermore, cells from TVA transgenic mice can be easily infected in vitro, allowing for facile introduction of genes to study their eects on primary cells. The future of TVA-based gene delivery, in combination with the current transgenic technologies, may lead us closer to a molecular understanding of tumorigenesis.
